Induced pluripotent stem cells and hepatic differentiation  by Chiang, Chih-Hung et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 76 (2013) 599e605
www.jcma-online.comReview Article
Induced pluripotent stem cells and hepatic differentiation
Chih-Hung Chiang a,b, Teh-Ia Huo a,c, Cho-Chin Sun b, Jung-Hung Hsieh b, Yueh Chien e,
Kai-Hsi Lu d,e,f,*, Shou-Dong Lee e,g
a Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC
bDivision of Urology, Department of Surgery, Taipei Veterans General Hospital and Su-Ao/Yuan-Shan Branch, Yi-Lan, Taiwan, ROC
cDivision of Gastroenterology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
dDepartment of Medical Research and Education, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC
eNational Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
fGraduate Institute of Basic Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, ROC
gDivision of Gastroenterology, Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, ROC
Received January 5, 2013; accepted March 20, 2013AbstractInduced pluripotent stem cells (iPSCs) are generated by reprogramming somatic cells to a pluripotent state by the introduction of specific
factors. They can be generated from cells of different origins, such as fibroblasts, keratinocytes, hepatocytes, and blood. iPSCs are similar to
embryonic stem cells (ESCs) in several aspects, such as morphology, expression of pluripotency markers, and the ability to develop teratoma that
contains tissue from three germ layers. In addition, iPSCs can undergo tridermal differentiation, including hepatic specific lineages. Considering
that iPSCs could be a source of hepatocyte regeneration, iPSC-based therapy has been widely implicated in the treatment of liver disease and
hepatic regeneration. In the present review, we discuss the therapeutic potential of iPSCs in hepatic repair and focus on the clinical applications
of iPSCs.
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1. Introduction ESCs are pluripotent stem cells derived from the inner cellAccording to the theory of ability differentiation, stem cells
can be classified into three categories. Totipotent stem cells,
which can be implanted in the uterus of a living animal and give
rise to a full organism, belong to the first category. Pluripotent
stem cells, which can give rise to every cell of an organism
except extraembryonic tissues, belong to the second category,
and this limitation is restricted to develop into a full organism.
Embryonic stem cells (ESCs) and induced pluripotent stem cells
(iPSCs) are typical types of pluripotent stem cells. Multipotent
stem cells, which are adult stem cells and only generate specific
lineages of cells, belong to the third category.* Corresponding author. Dr. Kai-Hsi Lu, Department of Medical Research
and Education, Cheng-Hsin General Hospital, 45, Cheng Hsin Street, Taipei
112, Taiwan, ROC.
E-mail address: lionel.lu@gmail.com (K.-H. Lu).
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http://dx.doi.org/10.1016/j.jcma.2013.07.007mass of mammalian blastocysts. Due to their remarkable
ability to proliferate indefinitely under appropriate in vitro
culture systems and their ability to differentiate into any cell
types of all three germ layers, differentiation of ESCs in vitro
provides a powerful model system for addressing questions
related to lineage commitment.1,2 Since human ESCs were
first isolated in 1998,3 ESCs have been regarded as a powerful
platform or tool in developmental studies, drug screening,
diseases treatment, tissue repair engineering, and regenerative
medicine. However, two main limitations have impeded the
application of ESC-based therapy. The first is the ethical
dilemma regarding human embryo donation and destruction,
and the second is that ESCs are incompatible with the immune
system of patients. To circumvent these deficiencies, scientists
worldwide have been devoted to the development of a variety
of reprogramming techniques to reverse somatic cells into a
stem cell-like state.hinese Medical Association. All rights reserved.
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that reprogramming somatic cells back to iPSCs could be ach-
ieved by retroviral transduction of four pluripotency-associated
transcription factorsdoctamer-binding transcription factor 4
(Oct3/4), sex determining region Y-box 2 (Sox2, SRY), V-myc
myelocytomatosis viral oncogene homolog (c-Myc), and
Kruppel-like factor 4 (Klf4).4 These iPSCs possessed morpho-
logical and molecular features that resemble those of ESCs.
They also gave rise to teratoma and germline-competent chi-
meras upon injection into blastocysts. This amazing finding
showed that cell fate could bemanipulated by certain genes, and
the discovery led to several distinguished awards, including the
Albert Lasker Basic Medical Research Award in 2009, and the
International Balzan Prize in 2010. In 2012, Dr. Shinya Yama-
naka and John Gurdon were awarded the Nobel Prize for
Physiology or Medicine for the discovery that mature cells can
be converted to stem cells. iPSCs have been generated in various
ways, including the exogenous gene delivery method,5e9
choosing multiple somatic cell sources,10e15 and induction of
iPSCs by small compounds16 to improve the efficiency of the
reprogramming process.
2. Comparison of iPSCs with ESCs
Generally, fully reprogrammed iPSCs display numerous
properties similar to those of ESCs. First, iPSCs are
morphologically identical to ESCs, and show infinite pro-
liferation and self-renewal abilities. They express pluripo-
tency markers such as TRA-1-60 antigens (TRA-1-60),
TRA-1-80 antigens (TRA-1-80), stage-specific embryonic
antigen 3 (SSEA-3), stage-specific embryonic antigen 4
(SSEA-4), octamer-binding transcription factor 4 (Oct4), sex
determining region Y-box 2 (Sox2, SRY), and Nanog ho-
meobox (Nanog).17e23 Typically, TRA-1-60 and SSEA-4 are
used as selection markers to distinguish fully reprogrammed
nascent colonies from partially reprogrammed ones. In
addition, iPSCs pass the hallmark test of pluripotency; when
injected into the testes of immunocompromised mice, they
form teratomas, showing their potential to differentiate into
the three embryonic germ layers. Moreover, the iPSCs also
contribute to germ line transmission.24 Several molecular
and functional assays were set to evaluate the similarity of
iPSCs to ESCs, including reactivation of self-renewal and
pluripotency associated genes, telomerase activity, X chro-
mosome, and stage-specific embryonic surface antigens,
suppression of somatic genes associated with cell of origin,
silencing of exogenous factors, capabilities in in vitro dif-
ferentiation, demethylation of promoters of pluripotency
genes, and in vivo teratoma formation, chimera contribution,
germline transmission, and tetraploid complementa-
tion.6,25,26 A recent study demonstrated that patient-specific
iPSCs from dermal fibroblasts of patients with long QT
syndrome can differentiate into functional cardiac myocytes,
but still recapitulated the electrophysiological features of the
disorder.27 Therefore, the major advantage of iPSCs over
ESCs, is that iPSCs can be derived from a patient’s own
somatic cells, thereby avoiding immune rejection aftertransplantation and the ethical concerns raised by using
ESCs.
3. Advances in reprogramming techniques
Based on their pluripotency, and that they are capable of
differentiating into any functional cell type, iPSCs possess
great potential for regenerative and therapeutic applications.
However, the group led by Dr. Yamanaka also reported that
those chimeras derived from mouse iPSCs, and their progeny
often develop tumors, mainly due to reactivation of c-Myc
transgene.28 Thus, numerous approaches to generate iPSCs
with lower tumorigenicity have been developed. Several
studies have shown that iPSCs generated without the c-Myc
virus demonstrated reduced tumor incidence in chimeric mice,
but the efficiency of iPSC creation is significantly
reduced.29,30 To overcome this dilemma, Okita et al found
another member of Myc, L-Myc, possessed stronger activity to
generate iPS and less tumorigenic activity.32
The use of genome-integrating retroviruses that are closely
related to tumor formation was another major limitation of the
original iPSC generation techniques. Thus, reprogramming
strategies with non-integrating systems seem to be the solution
to make iPSC-based therapy feasible. In 2008, Stadtfeld et al
established mouse iPSCs from fibroblasts and liver cells, by
non-integrating adenoviruses carrying four defined factors, and
suggested that insertional mutagenesis is not required for
in vitro reprogramming.31 At the same time, Okita et al suc-
cessfully generated iPSCs by transient transfection of two
plasmids containing complementary DNAs (cDNAs) encoding
four factors, eliminating the transgenic integration by the use of
retroviruses.32 More recent studies further described a “stem
cell cassette” or a polycistronic virus, a single lentiviral vector
composed of all four factors, and were able to yield iPSCs with
reduced insertional mutagenesis and viral reactivation.33,34
Another novel reprogramming technique using piggyBac
transposon was published in 2009.8,9,35 A polycistronic plasmid
harboring four factors and piggyBac transposon was con-
structed and integrated into the genome in the presence of
piggyBac transposase. As the reprogramming process was
achieved, the inserted fragment was easily removed by re-
expressing transposase. The transposon-based method elimi-
nates the use of virus, displays equivalent efficiencies to
retroviral transduction, excises integrated sequences without
genome alteration, and therefore represents a landmark prog-
ress toward therapeutically relevant virus-free iPSCs. To avoid
introducing exogenous genetic materials, two significant ad-
vances were reported. Zhou et al demonstrated that mouse fi-
broblasts could be fully reprogrammed by direct delivery of
recombinant reprogramming proteins.36 In 2010, an impressive
study by Luigi Warren and his colleagues showed a strategy for
reprogramming by administering synthetic mRNAs that code
for key factors, and by creating RNA-iPS (RiPS) cells.37 Both
techniques are safer, simpler, and faster approaches than the
currently established genetic method.
In human livers, hepatic progenitor cells are quiescent stem
cells with a low proliferating rate, and hepatic progenitor cells
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are continuously damaged or in cases of severe cell loss, or
inhibited in their replication.38,39 Stem cell niche refers to a
microenvironment where stem cells are found, which interacts
with stem cells to regulate cell fate and self-renewal. The
interaction with the specific microenvironmental cells is
thought to be a key mechanism in regulating the maintenance
of self-renewal and differentiation capacities by stem cells. In
the liver, the niche of hepatic progenitor cells is located at the
level of the canals of Hering and is composed of numerous
cells, such as hepatocytes, endothelial cells, hepatic stellate
cells, cholangiocytes, Kupffer cells, and inflammatory cells. It
has been reported that the autocrine and paracrine of Wnt
secretion and growth factors could interact and cross-talk with
progenitor cells, influence their proliferative and differentiate
processes in mice, rats, and humans.40,41
4. Advances in cell-based therapy
The development of stem cell studies makes cell trans-
plantation a promising therapy for diseases of the central
nervous system (CNS), including stroke, traumatic brain
injury, hypoxic encephalopathy, and degenerative disorders.42
Parkinson’s disease (PD) is the best candidate for cell
replacement therapy because only one group of cells, the
dopaminergic neurons, are affected. The main pathology of
PD is cellular loss of the substantia nigra pars compacta
dopaminergic neurons that project to the striatum.43 Clinical
signs of PD, which include rest tremor, rigidity, and bradyki-
nesia, are evident when about 80% of striatal and 50% of
nigral neurons are lost.44 Cell replacement therapy was first
attempted using fetal mesencephalic tissue, and the results
were successful in the earliest reports.42,45,46 However, adverse
effects and limitations were revealed in subsequent studies,
which included off-medication dyskinesia,47e49 graft-induced
inflammatory responses,50 and limited tissue availability.42
Hepatic progenitor cells represent a key target for devel-
oping new therapeutic approaches for end-stage chronic liver
diseases, and isolation and transplantation of hepatic progen-
itor cells could represent a new therapeutic approach for liver
diseases, as they offer many advantages to transplantation of
mature hepatocytes.51,52 The understanding of the autocrine
and paracrine pathways that regulate hepatic progenitor cell
proliferation during the progression of liver diseases could
open the possibility for the development of therapeutic stra-
tegies. Hepatic progenitor cells and their niche could repre-
sent, in the near future, a reserve stem cell compartment and a
target for therapeutic approaches to liver disease, based on
cell-specific drug delivery systems. The possibility of applying
stem cell therapy to end-stage chronic liver diseases represents
a critical and noteworthy goal in this field.
5. Differentiation of iPSCs toward hepatocytes
Orthotropic liver transplantation is the only established
treatment for end-stage liver disease. However, because of the
shortage of viable livers available for transplant, many patientsdie while still on a lengthy waiting list and many more are never
added to the list. Utilization of hepatocyte transplantation and
bioartificial liver devices have been proposed as alternative
therapeutic approaches to this problem.53,54 The major limita-
tion of cell therapies for liver diseases is the donor liver shortage.
How to efficiently obtain a large number of liver cells is a major
issue. These two approaches, however, require an unlimited
source of hepatocytes, and human primary hepatocytes provide
the most desirable solution for cell therapies. Yet, the utilization
of primary hepatocytes in therapy has been hindered by their
slow growth, loss of function, and de-differentiation in vitro.55
Because stem cells possess the ability to produce functional
hepatocytes for clinical applications and drug development,
such characteristics of stem cells may provide the answer to this
problem. In 2006, new discoveries in the mechanisms of liver
development and the emergence of iPSCs provided novel in-
sights into hepatocyte differentiation and the use of stem cells
for therapeutic applications.
iPSCs are defined as reprogrammed somatic cells that have
properties of pluripotent stem cells. Since the first report of the
generation of iPSCs by Takahashi and Yamanaka from mouse
fibroblasts in 2006,4 many studies have reported iPSC for-
mation from species including mouse, rat, monkey, and
human.56 Typically, iPSCs are generated by retroviral induc-
tion of transcription factors, Oct3/4, Sox2, KLF4, and c-Myc,
in fibroblasts.56 Lentivirus and adenovirus induction, induction
with other gene combinations, and virus-free approaches, such
as using plasmids, small molecules, and recombinant proteins,
have also been reported.56,57 This technical breakthrough in
creating iPSCs from somatic cells has implications for over-
coming the immunological rejection and the ethical issues
associated with the derivation of ESCs from embryos. In
addition, it has been shown that iPSCs can be generated from a
variety of cell types, such as pancreatic cells, meningiocytes,
keratinocytes, hematopoietic cells differentiated from ESCs,
and primary human hepatocytes.56,58,59 iPSCs provide a
potentially unlimited source for autologous cell therapy for
regenerative medicine. It has been shown that human (h)
iPSCs can be differentiated to many tissues, such as hemato-
poietic precursors and functional osteoclasts,60 pancreatic
insulin-producing cells,61 cardiomyocytes,62 photoreceptors,63
as well as neural conversion.64
Microarray analysis can present the most complete data set of
this issue. Applying powerful computational techniques and the
immense and growing database of known gene function to this
dataset allows new insights into how similar these processes are
on a global scale. To study this issue, we collected a large amount
of microarray data from databases to examine the transcriptional
programs of liver after partial hepatectomy, developing embry-
onic liver, ESCs, and iPSCs (Gene Expression Omnibus (GEO)
Series (GSE), GSE10806, GSE6933, GSE6945, GSE14012,
GSE10776, GSE6210, GSE10744, GSE6998).65e71 Principal
component analysis (PCA) allows large datasets to be devolved
into a few constructs that containmost of the variance. The results
of PCA demonstrated that the time series of gene expression
during liver regeneration does not segregate. Gene ontology
analysis revealed that liver retrieval after hepatectomy and liver
Fig. 1. The different expression gene ontology groups of liver differentiation. The microarray data from databases to check the transcription programs of liver after
partial hepatectomy, developing embryonic liver, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) are shown. The results of principal
component analysis (PCA) demonstrated that the time series of gene expression during liver regeneration does not segregate. Gene ontology analysis revealed that
liver retrieval after hepatectomy and liver development differ dramatically with regard to transcription factors and chromatin structure modification. The results of
gene ontology can be found when ESCs or iPSCs differentiate into liver progenitor cells, and turn on the mechanism of blood vessel development, coagulation, and
cell adhesion. Liver progenitor cells further differentiating into liver cells is needed to turn on the mechanism of oxidation reduction or metabolic process of fatty
acid and carboxylic acid.
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factors and chromatin structure modification (Fig. 1). iPSCs are
the preferred choice for hepatocyte generation because of their
pluripotency and potential source for autologous hepatocyte
transplantation. Differentiation of iPSCs toward a hepatic lineage
has been shown inmice72,73 and in humans74e76 involving similar
protocols as for hESCs. In addition, it was further shown that
human iPSCs generated from foreskin fibroblasts by lentiviral
transduction of OCT3/4, Sox2, Nanog, and Lin-28 homolog A
(LIN28) are capable of differentiating toward functional hepa-
tocytes by a four-step differentiation protocol and low oxygen
content. Importantly, these cells proliferated in mouse fetal liver
for 7 days after cell transplantation in vivo.74 Song et al reported
the differentiation of human iPSCs toward functional hepatocytes
with a multiphasic protocol, with 60% producing alpha-fetopro-
tein (AFP) and albumin, similar to hESCs differentiated to he-
patocytes.75 Sullivan et al generated three human iPS lines by
retroviral inductionofOct4,Sox2,Klf4, and c-Myc.They showed
that all three cell lines can differentiate to hepatic endoderm,
which they characterized with albumin and E-cadherin produc-
tion, AFP, hepatocyte nuclear factor-4a, and cytochrome P450
7A1 expression.76 This approach allows us to evaluate gene
expression during regeneration in the light of development and
assess whether the dominant developmental dimensions play a
significant role in regeneration. It was noted that regeneration
time points did not separate significantly when transformed with
developmental principal components and segregated away from
development time points. From the data of the microarrayanalysis, it can be found thatwhen theESCsor iPSCsdifferentiate
into liver progenitor cells, this will turn on the mechanism of
blood vessel development, coagulation, and cell adhesion. Also,
liver progenitor cells, further differentiated into liver cells, need to
turn on the mechanism of oxidation reduction or metabolic pro-
cess of fatty acid, carboxylic acid, etc.
6. Characterization and functional evaluation of iPSC-
derived hepatocytes
There is no consensus for the characterization of
hepatocyte-like cells derived from stem cells. Generally,
hepatocyte-like cells are recognized by their morphology,
liver-specific mRNAs, protein markers, and their functional
abilities in each phase of differentiation, which are delineated
by specific markers.77 Sox17, Goosecoid homeobox (GSC),
and Forkhead box A2 (FOXA2) are well-known markers of
definitive endoderm. Primary hepatic differentiation is often
assessed by the expression of HNF3b, AFP, and transthyretin
(TTR). The intermediate phase of hepatogenesis is recognized
by Hepatocyte nuclear factor 1, alpha (HNF1a), Hepatocyte
nuclear factor 4, alpha (HNF4a), albumin, and cytokeratin 18
(CK18). Finally, mature hepatocytes are defined by markers
tryptophan oxygenase (TO), tyrosine amino-transferase (TAT),
CCAAT/enhancer binding protein, alpha (C/EBPa), specific
cytochrome P450 superfamily (CYPs), and asialoglycoprotein
receptor 1(AGPR1).18,20,77 Several metabolic tests are used for
functional assays of differentiated hepatocytes. Glycogen
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one of the mature hepatocyte characteristics.18,20,78
Hepatocyte-specific functions, such as urea synthesis and al-
bumin production, are common functional evaluations in he-
patocyte differentiation.78 Uptake of low-density lipoprotein
(LDL) has also been utilized.18,20,79 Other hepatocyte-specific
functions have been evaluated infrequently, such as measure-
ment of coagulation factor VII activity80 and entry of HIV-
HCV pseudotype viruses into hESC-derived hepatic cells.79
7. Further challenges
Although progress towards the development of improved
protocols of hepatic-specific differentiation has been impres-
sive, a number of problems exist before the cells can be used
for cell transplantation trials in humans, or for toxicology or
pharmacology studies. For example, xeno-free and feeder-free
growth and differentiation conditions which are effective,
reproducible, robust, and relatively inexpensive, must be
established. This may include the development and use of
small molecules and synthetic biocompatible extracellular
matrix (ECMs) that can substitute for the extremely expensive
growth factors and xeno-derived ECMs. The disease model
with human iPSCs can offer a high throughput drug screening
platform. This platform has the potential to increase the effi-
ciency of drug development, while reducing costs and drug
depletion during development.81,82
Tumorigenicity is still one of the main obstacles in the
clinical application of hiPSC and hESC, and the major question
is how safe the cells must be before they can be used. Other
questions, such as how does one define a lack of tumorigenicity,
what is an acceptable risk, and how does one determine that a
differentiated cell population is free from the presence of any
early progenitor cells, must all be answered. Another major
issue to be resolved is the loss of proliferation of cells when they
become significantly differentiated. This leads to the question
of whether a sufficient number of mature hepatocyte-like cells
that have been derived from hESCs or hiPSCs can be obtained,
so that cell transplantation can be clinically effective. Another
question that has to be answered is at what stage cells that are
undergoing differentiation should be transplanted. Should they
be transplanted at an early progenitor stage when they are
rapidly proliferating yet immature, or transplanted until they
are fully differentiated yet much less proliferative?
Although these are but a few of the many technical ques-
tions that must be addressed in the coming years by in-
vestigators, the characteristics of reprogrammed adult somatic
cells without c-Myc, such as antioxidant properties and
mobilization behavior to injury sites, may prevent oxidative
stress-induced damage and provide an alternative for hepatic
regeneration in acute hepatic failure (AHF), as well as an
opportunity for further advances in hepatology research.
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